This study focuses on patients with Heart Failure with preserved Ejection Fraction (a condition where the heart’s pumping ability is maintained but it cannot fill properly with blood) and Metabolic Dysfunction Associated Steatotic Liver Disease (a condition where excess fat accumulates in the liver). The study will examine how glucagon, a hormone that helps regulate blood sugar levels, affects physical performance and metabolism when given as a continuous injection under the skin.
The treatment involves using GlucaGen, which will be mixed with Human Albumin (a blood protein) solution and given through a small needle placed under the skin. The purpose is to understand how glucagon affects the body’s maximum oxygen use during exercise and changes in energy usage in patients with these conditions.
During the study, participants will receive glucagon continuously for 4 hours through an injection under the skin. The researchers will measure how well patients can exercise and how their body uses energy while receiving the medication. They will also monitor how the medication moves through the body and its effects on various substances in the blood.
Germany 
